VRAX logo

VRAX
Virax Biolabs Group Ltd

6,119
Mkt Cap
$3.18M
Volume
2.87M
52W High
$1.20
52W Low
$0.10
PE Ratio
-0.13
VRAX Fundamentals
Price
$0.1596
Prev Close
$0.1589
Open
$0.152
50D MA
$0.1833
Beta
1.00
Avg. Volume
11.03M
EPS (Annual)
-$1.62
P/B
0.20
Rev/Employee
$333.21
$0.1667
Loading...
Loading...
News
all
press releases
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones...
PR Newswire·13d ago
News Placeholder
More News
News Placeholder
Breakthrough Science, AI Deals, and Nasdaq Warnings Collide in a High-Stakes Market Surge
A volatile mix of scientific breakthroughs, aggressive expansion, fresh capital inflows, and compliance risks is defining the current small- and micro-cap landscape. $KBLB, $RMSG, $VRAX, $ALMU, $IMA, $RCT, $NTRA, $ALLO, $RECT, $FFAI
24-7 Market News·14d ago
News Placeholder
AI and Biotech Enter a Stock Picker’s Market
The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT
24-7 Market News·27d ago
News Placeholder
What's Behind The Jump In Virax Biolabs Stock?
Shares of Virax Biolabs Group are soaring Tuesday after it secured several regulatory certifications paving the way for clinical validation.read more...
Benzinga·27d ago
News Placeholder
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD...
PR Newswire·27d ago
News Placeholder
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
News Placeholder
Penny Stocks To Keep An Eye On - December 3rd
iRobot, Richtech Robotics, Bitfarms, Virax Biolabs Group, Nauticus Robotics, Incannex Healthcare, and Fusion Fuel Green are the seven Penny stocks to watch today, according to MarketBeat's stock...
MarketBeat·5mo ago
News Placeholder
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement PR Newswire LONDON, Dec. 4, 2025 Extends...
PR Newswire·5mo ago
News Placeholder
Promising Biotech Stocks To Consider - December 3rd
Capricor Therapeutics, Vertex Pharmaceuticals, Danaher, BioNTech, and Virax Biolabs Group are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...
MarketBeat·5mo ago
News Placeholder
Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally
VRAX shares fell 12.79% in after-hours trading following a $5 million private placement announcement.read more...
Benzinga·5mo ago
<
1
2
...
>

Latest VRAX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.